CLINICAL TRIALS PROFILE FOR SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
✉ Email this page to a colleague
All Clinical Trials for Sulfur Hexafluoride Lipid-type A Microspheres
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03040323 ↗ | Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses | Terminated | Indiana University | Phase 4 | 2016-12-22 | The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast. |
| NCT03300401 ↗ | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | Withdrawn | National Cancer Institute (NCI) | N/A | 2017-11-07 | This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor. |
| NCT03300401 ↗ | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | Withdrawn | University of Southern California | N/A | 2017-11-07 | This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor. |
| NCT03407001 ↗ | Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis | Completed | National Cancer Institute (NCI) | Early Phase 1 | 2018-01-12 | This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent. |
| NCT03407001 ↗ | Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis | Completed | M.D. Anderson Cancer Center | Early Phase 1 | 2018-01-12 | This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Sulfur Hexafluoride Lipid-type A Microspheres
Condition Name
Clinical Trial Locations for Sulfur Hexafluoride Lipid-type A Microspheres
Trials by Country
Clinical Trial Progress for Sulfur Hexafluoride Lipid-type A Microspheres
Clinical Trial Phase
Clinical Trial Sponsors for Sulfur Hexafluoride Lipid-type A Microspheres
Sponsor Name
